Post-ischemic reactive blood flow (RBF) measured by Xe-133 clearance method was studied from the view point of diagnostic use and of evaluation of therapeutic effect of medications in peripheral vascular diseases.
The present work includes methodological observation and study of the relation between the RBF and clinical symptom of arteriosclerosis obliterans (ASO) followed up before and after Pyridlnolcarbamate administration.
1) Repeat variability of RBF
RBF was measured twice at 2-4 weeks interval in 9 normal legs and in 17 abnormal legs with ASO.
The ratio of the first to the second measurement (1st/2nd) were ranged from maximum 1.63 to minimum 0.57 and mean & S. D. was 1.067±0.3035 (P<0.05).
2) One year natural course of RBF in a patient with ASO
The mean & S. E. in 6 serial RBF measurements without any treatment was 11.82±1.03ml in the right leg and 10.15±0.82ml in the left leg. Coefficients of variation were 25% in the right and 23% in the left.
3) RBF
The means & S. E.'s were 10.59±0.61ml in 46 legs with intermittent claudication, 11.80±1.37ml in 9 legs without intermittent claudication with ASO, and 21.69±1.22ml in 20 normal legs.
The difference between the normal and the patient with ASO were statistically significant (P<0.01). But there was no statistical significance between the legs with and without intermittent caludication in patients with ASO.
4) Latency time and RBF
Latency time, the duration from the cuff opening to the begining of the down slope in Xe-133 clearance curve had tendency to be prolonged with the RBF decreased.
5) Toe-plethysmogram and RBF
RBF was decreased in the groups with the crest time prolonged more than 0.3 seconds compared to the subjects with normal crest time (p<0.01 or p<0.05).
The ratio of pulse amplitude in toe-pletysmogram before and after reactive hyperemia was decreased in the groups in which RBF was decreased. There were statistically significant differences among four groups (p<0.01 or p<0.05).
6) Clinical signs and RBF
3 cases were presented showing how the changes in RBF were parallel to the clinical signs and symptoms.
After pyridinolcarbamate adminisration, the RBF was increased with improvement of intermittent claudication in 3 of all 6 patients.
However, there was no significant change in RBF in 2 of all 6 patients in spite of clinical improvement.
In one of all 6 patients, RBF was fluctuated according to the fluctuation of intermittent claudication.
View full abstract